Table 2.

Univariate and multivariate analyses for progression-free survival cohort

	Univariate analysis		Multivariate analysis
Parameter	HR (95% CI)	p value	HR (95%CI)	p value
Aspirin use
Yes vs. No	0.48 (0.32 - 0.71)	< 0.001	0.45 (0.30 - 0.66)	< 0.001
CNS
No vs. Yes	0.60 (0.45 - 0.81)	0.001	0.58 (0.44 - 0.76)	< 0.001
Age
< 60 vs. ≥ 60	1.18 (0.88 - 1.56)	0.260	0.73 (0.55 - 0.96)	0.027
Performance status
0 - 1 vs. ≥ 2	0.25 (0.16 - 0.38)	< 0.001	0.25 (0.17 - 0.28)	< 0.001
Smoke status
Never vs. Former/current	0.98 (0.71 - 1.35)	0.90	1.09 (0.8 - 1.47)	0.570
Gender
Male vs. Female	1.33 (0.99 - 1.78)	0.062	1.22 (0.92 - 1.61)	0.170
Lines of TKI therapy
Line 1 vs. Line ≥ 2	0.81 (0.59 - 1.11)	0.190	0.68 (0.50 - 0.93)	0.015

Abbreviations: CNS – central nervous system, TKI – tyrosine kinase inhibitor